Promising Antitumor Activity Observed Following Treatment With Eftilagimod Alpha Plus Pembrolizumab for ICI-Resistant Advanced NSCLC

Article

A challenging patient population with advanced non–small cell lung cancer and resistance to common immunotherapeutics appeared to derive promising benefit from treatment with eftilagimod alpha plus pembrolizumab.

Second-line treatment with the soluble LAG-3 protein eftilagimod alpha in combination with pembrolizumab (Keytruda) yielded promising antitumor responses in a population of patients with metastatic non–small cell lung cancer with limited treatment options following progression on a PD-1/L1 inhibitor, according to findings from the phase 2 TACTI-002 trial (NCT03625323) presented at the 2022 World Conference on Lung Cancer.

The treatment yielded an overall response rate of 5.6% in the intent-to-treatment population (n = 36) by both iRECIST and RECIST 1.1 criteria, all of which were partial responses. A total of 11 and 10 patients, respectively, achieved stable disease by each criterion and 22 and 23 patients had progressive disease. Moreover, the disease control rate was 36.1% by iRECIST criteria and 33.3% by RECIST 1.1 criteria.

Eftilagimod alpha targets a subset of MHC class II molecules that mediate activation of antigen presenting, natural killer, and T cells. Investigators believed that stimulating the dendritic cell network that leads to T-cell recruitment and activation could be a viable means to overcome PD-1 inhibitor resistance.

Eftilagimod alpha was administered at a dose of 30 mg subcutaneously every 2 weeks for the first 8 three-week cycles followed by once per cycle for the next 9 cycles plus pembrolizumab at a 200-mg dose every 3 weeks for 2 years. A total of 36 patients were included in the study from April 2019 to August 2021.

Investigators reported that 75% of patients had PD-L1–low, defined as a tumor proportion score of 1% to 49%, or PD-L1–negative disease. Moreover, 66.7% of patients were previously treated with a regimen consisting of chemotherapy plus an anti–PD-1 or PD-L1, with 41.7% not responding to their first line treatment. The median patient age was 67 years (range, 46-84) and most patients were men (61.1%). Additionally, most patients were current or previous smokers (86.1%) with nonsquamous pathology (77.8%).

The median overall survival (OS) in the intent to treat population was 9.7 months with a OS rate of 72.2% at 6 months,

A challenging patient population with advanced non–small cell lung cancer and resistance to common immunotherapeutics appeared to derive promising benefit from treatment with eftilagimod alpha plus pembrolizumab.

TABLE. A challenging patient population with advanced non–small cell lung cancer and resistance to common immunotherapeutics appeared to derive promising benefit from treatment with eftilagimod alpha plus pembrolizumab.

43.4% at 12 months, and 36.5% at 18 months. Moreover, investigators also reported outcomes by PD-L1 expression. OS results were also reported based on PD-L1 expression (Table).

Adverse effects (AEs) of any grade were reported in 97.2% of patients, with 19.4% experiencing any serious AEs. Grade 3 or higher AEs occurred in 33.3% of patients. Two fatalities occurred (5.6%), neither of which were related to treatment.

Common toxicities of any grade included decreased appetite (33.3%), dyspnea (30.6%), cough (27.8%), asthenia (22.2%), and fatigue (19.4%). Grade 3 AEs included dyspnea (2.8%), asthenia (2.8%), fatigue (2.8%), and arthralgia (2.8%), with 1 event of grade 4/5 dyspnea (2.8%). Any-grade AEs associated with treatment included asthenia (13.9%), injection site erythema (13.9%), and injection site reaction (11.1%). There were no treatment-related death or drug discontinuations.

Reference

Forster M, Krebs MG, Majem M, et al. Results from a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in 2nd line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma (NSCLC) patients. Presented at: 2022 World Conference on Lung Cancer; August 6-9, 2022; Vienna, Austria; Abstract EP08.01-109.

Related Videos
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
A panel of 3 experts on lung cancer
A panel of 3 experts on lung cancer
A panel of 3 experts on lung cancer
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Related Content